DBV Technologies DBVT Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$10.45 up $0.65, 6.63% at close Nov 6
Last close · Previous close $9.80
- Market cap
- At the Nov 6 close
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$3.00Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$10.45up $0.65, 6.63%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$9.80Nov 5
- Volume210.65KNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume413.69KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $8.63 to $26.19; now $10.45
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
DBVT beat the S&P 500 in 1 of 7 periods.
| Period | DBVT and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | DBVT: up 4.7% S&P 500: down 5.6% | DBVT beat the S&P 500 by 10.3 percentage points Beat |
| 3M | DBVT: down 23.9% S&P 500: down 4.1% | DBVT trailed the S&P 500 by 19.8 percentage points Trailed |
| YTD | DBVT: down 45.5% S&P 500: up 8.7% | DBVT trailed the S&P 500 by 54.2 percentage points Trailed |
| 1Y | DBVT: down 25.6% S&P 500: up 10.9% | DBVT trailed the S&P 500 by 36.5 percentage points Trailed |
| Long term | ||
| 3Y | DBVT: up 4.5% S&P 500: up 75.0% +1.5% vs +20.5% a year | DBVT trailed the S&P 500 by 70.5 percentage points Trailed |
| 5Y | DBVT: down 65.3% S&P 500: up 67.8% −19.1% vs +10.9% a year | DBVT trailed the S&P 500 by 133.1 percentage points Trailed |
| 10Y | DBVT: down 97.0% S&P 500: up 313.1% −29.5% vs +15.2% a year | DBVT trailed the S&P 500 by 410.1 percentage points Trailed |
$10,000 invested in DBVT 10 years ago (Nov 4, 2016) would be worth about $301 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
DBVT beat the S&P 500 in 1 of 7 periods.
| Period | DBVT and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | DBVT: up 4.7% S&P 500: down 5.6% | DBVT beat the S&P 500 by 10.3 percentage points Beat |
| 3M | DBVT: down 23.9% S&P 500: down 4.3% | DBVT trailed the S&P 500 by 19.6 percentage points Trailed |
| YTD | DBVT: down 45.5% S&P 500: up 7.8% | DBVT trailed the S&P 500 by 53.3 percentage points Trailed |
| 1Y | DBVT: down 25.6% S&P 500: up 9.7% | DBVT trailed the S&P 500 by 35.3 percentage points Trailed |
| Long term | ||
| 3Y | DBVT: up 4.5% S&P 500: up 68.8% +1.5% vs +19.1% a year | DBVT trailed the S&P 500 by 64.3 percentage points Trailed |
| 5Y | DBVT: down 65.3% S&P 500: up 56.9% −19.1% vs +9.4% a year | DBVT trailed the S&P 500 by 122.2 percentage points Trailed |
| 10Y | DBVT: down 97.0% S&P 500: up 252.6% −29.5% vs +13.4% a year | DBVT trailed the S&P 500 by 349.6 percentage points Trailed |
$10,000 invested in DBVT 10 years ago (Nov 4, 2016) would be worth about $301 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$493.60
Closing high on . Now 97.9% below that record.
Split-adjusted daily closes since Oct 22, 2014.
Stock splits
2
Latest: 1-for-5 on . Share counts adjust after each split.
Both splits
- 1-for-5
- 1-for-2
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q3 FY26, the quarter ended Sep 30, 2026. “Last 12 months” means the four quarters from Oct 1, 2025 to Sep 30, 2026, and balance-sheet figures are as of Sep 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $3.85Mdown 31.5%
- Net income
- −$207.33M
- Diluted EPS
- −$3.00
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q4 FY24 (Dec 31, 2024) | $511.00K | −$23.02M | −$1.10 |
| Q1 FY25 (Mar 31, 2025) | $800.00K | −$27.10M | −$1.30 |
| Q2 FY25 (Jun 30, 2025) | $1.50M | −$41.90M | −$1.55 |
| Q3 FY25 (Sep 30, 2025) | $2.80M | −$33.20M | −$1.20 |
| Q4 FY25 (Dec 31, 2025) | $645.00K | −$44.83M | −$1.15 |
| Q1 FY26 (Mar 31, 2026) | $900.00K | −$47.60M | −$0.55 |
| Q2 FY26 (Jun 30, 2026) | $700.00K | −$50.40M | −$0.60 |
| Q3 FY26 (Sep 30, 2026) | $1.60M | −$64.50M | −$0.70 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $5.71M | −$97.81M | Paused See the note under the price. |
| FY22 (Dec 31, 2022) | $4.84M | −$96.27M | Paused See the note under the price. |
| FY23 (Dec 31, 2023) | $15.73M | −$72.73M | Paused See the note under the price. |
| FY24 (Dec 31, 2024) | $4.15M | −$113.92M | −$5.85 |
| FY25 (Dec 31, 2025) | $5.64M | −$146.95M | −$5.25 |
Margins
- Gross 100.0%
- Operating −5,413.6%
- Net −5,392.2%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$191.75MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$188.37MLast 12 months
- Capital spending$3.37MLast 12 months
- −4,986.9%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $295.86MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $165.70MAs of Sep 30, 2026
Cash plus short- and long-term marketable securities on the Sep 30, 2026 balance sheet.
- Total debt$7.50MAs of Sep 30, 2026
- Net cash$158.20MAs of Sep 30, 2026
- 3.24As of Sep 30, 2026
Current assets divided by current liabilities on the Sep 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.05As of Sep 30, 2026
Total debt divided by shareholders’ equity on the Sep 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 3 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✗Net income was positive: not passed
- ✗Operating cash flow was positive: not passed
- ✗Return on assets improved: not passed
- ✓Operating cash flow exceeded net income: passed
- ✓Long-term debt fell relative to assets: passed
- ✓Current ratio improved: passed
- ✗Share count didn’t rise: not passed
- ✗Gross margin improved: not passed
- ✗Asset turnover (revenue ÷ assets) improved: not passed
- −120.9%Last 12 months
Over the last 12 months, DBV Technologies lost money: its net loss was 120.9% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −88.3%Last 12 months
Over the last 12 months, DBV Technologies’s net loss was 88.3% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About DBV Technologies
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. The company provides Diallertest Milk, a diagnostic product for the detection of cows milk protein allergy (CMPA) in children. Its products include Viaskin Peanut, an immunotherapy product for the treatment peanut allergies in children, adolescents, and adults; Viaskin Milk for the treatment of CMPA and milk-induced eosinophilic esophagitis (EoE); and Viaskin Egg, a development program for the treatment of hens egg allergy. The company also develops other earlier stage product development programs, which comprise house dust mites allergy, EoE, pertusiss boost vaccine, and birch pollen allergy. DBV Technologies S.A. was founded in 2002 and is based in Bagneux, France.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- France
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
DBVT news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
DBVT stock FAQ
What is DBVT stock’s price today?
DBV Technologies (DBVT) traded at $10.45 at the close on , up $0.65 (6.63%) from the previous close of $9.80. Over the past 52 weeks it has traded between $8.63 and $26.19.
If you invested $1,000 in DBVT 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in DBVT on would be worth about $30 at the close on , a total return of −97.0%. The same $1,000 would be worth $347 if invested five years ago and $744 if invested one year ago. Past performance doesn’t predict future returns.
What is DBVT’s P/E ratio?
DBVT’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$3.00).
How much revenue does DBV Technologies make?
DBV Technologies reported $3.8 million of revenue over the four quarters to , down 31.5% from the twelve months before. In its latest quarter (Q3 FY26, ended ) revenue was $1.6 million, down 42.9% from a year earlier.
Is DBV Technologies profitable?
Not over the four quarters to . DBV Technologies reported a net loss of $207.3 million across those four quarters on $3.8 million of revenue.
What are DBVT’s earnings per share?
DBVT’s diluted earnings per share were −$3.00 over the four quarters to , compared with −$5.15 in the twelve months before. The latest quarter (Q3 FY26) brought −$0.70 per share, against −$1.20 a year earlier (how EPS works).
Does DBVT pay a dividend?
DBV Technologies hasn’t paid a dividend in the last twelve months.
What is DBVT’s 52-week high and low?
Over the past 52 weeks DBVT has traded as low as $8.63 and as high as $26.19. At $10.45 at the close on , it is 60.1% below that high and 21.1% above the low.
What is DBVT’s all-time high?
DBVT’s highest closing price was $493.60 on , adjusted for stock splits. At $10.45 at the close on , it is 97.9% below that record.
Has DBVT stock ever split?
Yes, twice: 1-for-2 on ; 1-for-5 on .
How has DBVT stock performed?
Including dividends and measured to the close on , DBVT has returned −45.5% so far this year and −25.6% over the past year, and −65.3% over five years (−19.1% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is DBV Technologies in?
DBV Technologies is in the Healthcare sector and the Biotechnology industry, and is headquartered in France.
What exchange does DBVT trade on?
DBV Technologies trades on the Nasdaq under the ticker symbol DBVT. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.